Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV001011736 | SCV001172093 | pathogenic | Hereditary cancer-predisposing syndrome | 2023-05-19 | criteria provided, single submitter | clinical testing | The c.1474_1475delAAinsG pathogenic mutation, located in coding exon 10 of the FLCN gene, results from the deletion of two nucleotides and insertion of one nucleotide causing a translational frameshift with a predicted alternate stop codon (p.N492Afs*21). This alteration occurs at the 3' terminus of the FLCN gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 68 amino acids of the protein. However, premature stop codons are typically deleterious in nature and the impacted region is critical for protein function (Ambry internal data). Other alterations predicted to result in 3' terminus truncation have been detected in individuals who met clinical diagnostic criteria for Birt-Hogg-Dubé Syndrome (Schmidt LS et al. Am. J. Hum. Genet. 2005 Jun;76:1023-33; Lim DH et al. Hum. Mutat. 2010 Jan;31(1):E1043-51; Ambry internal data). In addition, this variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |